Genetic Immunity Presents DermaVir at DNA Vaccines 2010 Conference – Unique Nanomedicine Formulation and Topical Administration of an HIV/AIDS Therapeutic Vaccine

Published: Mar 02, 2010

BUDAPEST, Hungary & MCLEAN, Va.--(BUSINESS WIRE)--Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine vaccines, will present data at this week’s DNA Vaccines 2010 in New Orleans, LA concerning the formulation and topical administration of the DermaVir therapeutic vaccine for HIV/AIDS. DNA Vaccine 2010 invites leading scientists to report on the latest research in the progressive field of DNA or Genetic Vaccines.

Back to news